tetano
Editor, Senior Moderator
EMBO Mol Med. 2020 Apr 25. doi: 10.15252/emmm.202012465. [Epub ahead of print]
COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E[SUP]1,[/SUP][SUP]2[/SUP], Tsiodras S[SUP]3,[/SUP][SUP]4[/SUP].
Author information
Abstract
Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183.470 deaths[SUP]$[/SUP] [CAN YOU PLEASE MAKE IT A FOOTNOTE? [SUP]$[/SUP] JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6].. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNλ), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNλ in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNλ induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNλ and potential safety considerations. We conclude that IFNλ constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; cytokine storm; hyperinflammation; interferon; viral infection
PMID:32333818DOI:10.15252/emmm.202012465
Free full text
COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E[SUP]1,[/SUP][SUP]2[/SUP], Tsiodras S[SUP]3,[/SUP][SUP]4[/SUP].
Author information
Abstract
Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183.470 deaths[SUP]$[/SUP] [CAN YOU PLEASE MAKE IT A FOOTNOTE? [SUP]$[/SUP] JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6].. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNλ), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNλ in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNλ induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNλ and potential safety considerations. We conclude that IFNλ constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; cytokine storm; hyperinflammation; interferon; viral infection
PMID:32333818DOI:10.15252/emmm.202012465
Free full text